Skip to main content
Clinical Trials/NCT04412304
NCT04412304
Completed
Not Applicable

Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden

Karolinska Institutet1 site in 1 country166 target enrollmentMarch 6, 2020

Overview

Phase
Not Applicable
Intervention
Dose of Tinzaparin or Dalteparin
Conditions
Covid-19
Sponsor
Karolinska Institutet
Enrollment
166
Locations
1
Primary Endpoint
28-days ICU mortality
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

Registry
clinicaltrials.gov
Start Date
March 6, 2020
End Date
May 28, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christer Svensen

Professor

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • laboratory confirmed positive test for SARS-CoV-2
  • admitted to ICU because of critical illness due to covid-19

Exclusion Criteria

  • patients with treatment for thromboembolic complications at arrival to the ICU
  • short ICU length of stay defined as discharged the same or the following day as ICU admission

Arms & Interventions

thrombose prophylaxis

The dose used to prevent thromboembolic complication in critically ill

Intervention: Dose of Tinzaparin or Dalteparin

double thrombose prophylaxis

Double the dose used to prevent thromboembolic complication in critically ill

Intervention: Dose of Tinzaparin or Dalteparin

full dose anticoagulant

Dose used to treat thromboembolic event

Intervention: Dose of Tinzaparin or Dalteparin

Outcomes

Primary Outcomes

28-days ICU mortality

Time Frame: 28 days from ICU-admission

28-days ICU mortality from admission to the ICU. Discontinue of ICU-care to palliative care counts as death.

Secondary Outcomes

  • Incidence of thromboembolic events(28 days from ICU-admission)
  • Incidence of bleeding events(28 days from ICU-admission)
  • ICU-free days alive from ICU-admission.(28 days from ICU-admission)

Study Sites (1)

Loading locations...

Similar Trials